• FEES
  • REQUEST AN APPOINTMENT
  • SUBSCRIBE TO OUR MAILING LIST
  • Contact Us
Direct Line +61 426 428 156
HealthFlex
×
  • HOME
  • i3 SERVICES
  • i3 SAMPLE PROJECTS
  • i3 REPORTS
  • i3 Clinical Trials Report
  • i3 SHOP
  • i3 PARTNERSHIPS
  • i3 QoW

i3 Consult to Expand It’s CTR Reporting for Observational Studies in Pre-Approval and Post Marketing for Mobile OS Application

i3 Consult to Expand It’s CTR Reporting for Observational Studies in Pre-Approval and Post Marketing for Mobile OS Application
April 29, 2019adminNews

Back in December last year i3 Consult launched its CTR Reporting Services for Observational Studies . Just to re-iterate the unique selling point of these services, i3 Consult through its weekly clinical trial reports (CTR) on new drug therapies currently in clinical trials worldwide, we are seeking to use our CTR database as real world evidence in helping our clients to address the following critical success issues:

  • Is the research sufficiently patient-focused?
  • Have sufficient observational studies been used in the pre-approval and post market stages?
  • Are there further opportunities for observational study data to save you time and money in your current clinical trial investigation?
  • How observational studies can make a viable alternative to clinical trials or bridging studies.
  • To identify stakeholders and determine what kind of observational research data is needed.

At i3 Consult we believe that Mobile OS applications can be harnessed in clinical trials to identify blind spots and moreover address novel clinical endpoints that would have been impractical or intractable based on previous modes of clinical trial reporting. Mobile OS Application derived observational studies particularly at the pre-approval or even post marketing stages of clinical trials have the added benefit of being more efficient and patient friendly to trial participants while contributing to the real world patient focused understanding of the sponsor’s candidate medicine otherwise gathered in isolated clinical or research settings.

We will continue to develop and expand in this exciting area as the Clinical Trials Transformation Initiative (CTTI) unfolds and more and more of our clients come to realise the enormous potential of such technology-derived novelty.

Add Comment Cancel

You must be logged in to post a comment.

Categories

  • News
  • Uncategorized

Recent Posts

  • 2021 Launch: BioPitch.Live
  • A Timely i3 Quote of the Week (i3 QoW)
  • Facing the Challenges in a COVID-19 Era
  • i3 Consult: Using block chain technology in clinical trials to better help our clients.
  • i3 Consult : i3 Framework Services

Recent Comments

    Archives

    • January 2021
    • July 2020
    • May 2020
    • December 2019
    • October 2019
    • September 2019
    • June 2019
    • April 2019
    • March 2019
    • February 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • April 2018
    • February 2018
    • December 2017
    • October 2017
    • September 2017
    • March 2017

    logo

    i3 Consult is endowed with a broad range and depth of in-house skills with specialist expertise consolidated from a stringent selection of outsourced associates.

    +61 426 428 156,+33 788914240

    i3consult@i3consult.com

    https://www.i3consult.com

    France Office: 3 Place de l’Eglise, Liglet, Vienne, 86290. Australia Office: 1001/160 Roma Street, Brisbane, Qld. Australia 4000.

    Latest News and Press Release

    • 2021 Launch: BioPitch.Live Jan 7

      To kick start 2021, i3 Consult in partnership with iClinical,...

    • A Timely i3 Quote of the Week (i3 QoW) Jul 8

      "Pandemic is not a word to use lightly or carelessly....

    • Facing the Challenges in a COVID-19 Era May 30

      First and foremost, i3 Consult hopes that you and your...

    • i3 Consult: Using block chain technology in clinical trials to better help our clients. Dec 2

      Reproducibility, data sharing, personal data privacy concerns and patient enrolment...

    Get Us on Social Media

    Tweet to Us on @i3_Consult

    Quick Links

    • HOME
    • i3 SERVICES
    • i3 SAMPLE PROJECTS
    • i3 REPORTS
    • i3 Clinical Trials Report
    • i3 SHOP
    • i3 PARTNERSHIPS
    • i3 QoW
    Copyright ©i3 Consult 2021 All rights reserved.
    Click this link to view our Privacy Policy